Australian Patent Amendments To Trade Pact Face Scrutiny From PhRMA, USTR
This article was originally published in The Pink Sheet Daily
Executive Summary
Last-minute changes to the Australian law implementing the free trade deal may violate the underlying agreement and WTO rules on patent rights, PhRMA says. The amendments are designed to block “evergreening” practices by brand name drug makers.